A modified gemcitabine plus capecitabine regimen Proteasome inhibitor may be evaluated in patients with metastatic renal cell cancer after failure of approved targeted therapies.”
“Purpose: We evaluated the prognostic roles of metastasectomy
and an established risk stratification system in patients with &sease recurrence following nephrectomy for nonmetastatic renal cell carcinoma.
Materials and Methods: A retrospective analysis was performed in 129 patients with localized renal cell carcinoma treated with partial or radical nephrectomy and subsequently diagnosed with disease recurrence. At recurrence a previously validated risk score based on Karnofsky performance status, interval from nephrectomy, and serum hemoglobin, calcium and lactate dehydrogenase was used to categorize patients as being at favorable, intermediate or poor risk. Survival from time of recurrence was assessed based on risk categorization and metastasectomy.
Results: Median time from
nephrectomy to recurrence was 16 months. The risk score was strongly associated with median survival and the 2-year survival rate, including 73 months and 81% for favorable risk, 28 months and 54% for intermediate risk, and 6 months and 11% for poor risk, respectively (log rank < 0.001). Metastasectomy performed in 44 patients (34%) was found to be of clinical benefit across the various risk categories (interaction analysis p = 0.8). On multivariate analysis a botter risk category and metastasectomy were each independently associated with more favorable survival (each p < 0.001). When combined, they provided 6 risk categories with an estimated www.selleckchem.com/products/gw2580.html 2-year survival of 0% to 93%.
Conclusions: MRIP The clinical course in patients with recurrent renal cell carcinoma following nephrectomy can be variable. It is independently impacted by an objectively determined risk score and whether the patient undergoes metastasectomy.”
“Purpose: We assessed the impact of lymphovascular invasion on the prognosis of patients treated for clinically localized
(pT1-3N0M0) upper tract urothelial carcinoma.
Materials and Methods: From January 1998 to December 2004, 106 patients treated surgically for clinically localized upper tract urothelial carcinoma (pT1-3cN0M0) were recruited for analysis retrospectively. We assessed the impact of multiple prognostic factors including age, sex, smoking, tumor multiplicity, pathological stage, grading, squamous differentiation, subsequent bladder tumor recurrence, tumor site and lymphovascular invasion on the recurrence-free survival rate. We clarified the role of lymphovascular invasion in predicting cancer specific survival in these patients.
Results: Mean patient age was 67.2 +/- 11.1 years and median followup was 47.5 months (range 40 to 115). Lymphovascular invasion was present in 32 of 106 (30.2%) patients.